Mark J. Ratain to Reproducibility of Results
This is a "connection" page, showing publications Mark J. Ratain has written about Reproducibility of Results.
Connection Strength
0.475
-
Randomized phase II trials: a long-term investment with promising returns. J Natl Cancer Inst. 2011 Jul 20; 103(14):1093-100.
Score: 0.249
-
Cancer pharmacogenomics: strategies and challenges. Nat Rev Genet. 2013 Jan; 14(1):23-34.
Score: 0.069
-
Pharmacokinetic variability of anticancer agents. Nat Rev Cancer. 2005 Jun; 5(6):447-58.
Score: 0.041
-
Validation of a Large Custom-Designed Pharmacogenomics Panel on an Array Genotyping Platform. J Appl Lab Med. 2021 11 01; 6(6):1505-1516.
Score: 0.032
-
Establishment of CYP2D6 reference samples by multiple validated genotyping platforms. Pharmacogenomics J. 2014 Dec; 14(6):564-72.
Score: 0.019
-
A novel fully automated molecular diagnostic system (AMDS) for colorectal cancer mutation detection. PLoS One. 2013; 8(5):e62989.
Score: 0.018
-
Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue. PLoS Genet. 2011 May; 7(5):e1002078.
Score: 0.015
-
Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. Physiol Genomics. 2008 Apr 22; 33(2):278-91.
Score: 0.012
-
Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide. Clin Pharmacol Ther. 2002 Dec; 72(6):638-47.
Score: 0.009
-
Simultaneous determination of 5-fluorouracil and uracil by high-performance liquid chromatography using four serial columns. J Chromatogr B Biomed Sci Appl. 1998 Dec 11; 720(1-2):245-50.
Score: 0.007
-
A population model for the leukopenic effect of etoposide. Clin Pharmacol Ther. 1995 Mar; 57(3):325-34.
Score: 0.005